Improving Patient Access and Resource Allocation in HCV: Focus on Screening Practices and Therapeutic Advances

Improving Patient Access and Resource Allocation in HCV: Focus on Screening Practices and Therapeutic Advances

Live Webinar
Faculty

H. Eric Cannon, PharmD, FAMCP
Chief of Pharmacy
SelectHealth
Murray, Utah

Robert G. Gish, MD
Senior Medical Director
St Josephs Hospital and Medical Center
Liver Program
Phoenix, Arizona
Clinical Professor of Medicine
University of Nevada
Las Vegas, Nevada

Q&A Co-Hosts

Jeffrey D. Dunn, PharmD, MBA
Chief Clinical Officer/Senior Vice President
VRx Pharmacy
Salt Lake City, Utah

Richard A. Manch, MD, FAASLD, FACP, FACG
Chief of Hepatology
St. Joseph’s Hospital and Medical Center, Phoenix
Clinical Professor of Medicine, University of Arizona 
Phoenix, Arizona

Intended Learners

This activity is designed for pharmacy directors, medical directors, and other decision makers working in managed care organizations.

Learning Objectives

After completing this activity, participanets should be able to:

  • Quantify the burden of chronic HCV infection in terms of clinical, societal, and economic impact
  • Enact plan wide programs to align HCV screening of covered patients with best practices
  • Identify the challenges of traditional, interferon-based HCV treatment and the clinical implications of suboptimal treatment
  • Evaluate the safety and efficacy of newer direct-acting antiviral (DAA) HCV pharmacotherapies, including the implications of all oral regimens, single pill formulations, and pangenotypic treatments
  • Apply current DAA guidance and clinical/pharmacoeconomic data to formulary discussions and benefit design
Activity Overview

In order to be eligible for documentation of credit, participants must complete the pre-test, attend the full webinar, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

There is no fee associated with this activity.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

For questions regarding this educational activity, please call 609-371-1137.

 

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs (please download here). A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Accreditation

  In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This activity is approved for 1.0 contact hour (.1 CEUs) of continuing pharmacy education (0276-0000-17-053-L01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Kyle R. Copeland, PharmD, BCPS, Clinical Specialist Pharmacist, Parkwest Medical Center and Assistant Professor, University of Tennessee College of Pharmacy, Knoxville, Tennessee.

Planning Committee

The planning committee comprises H. Eric Cannon, PharmD, FAMCP and Robert G. Gish, MD; Kyle R. Copeland, PharmD, BCPS; and Donna Brophy, Kristin Ciszeski, Mary Johnson, Susan Kuhn, Michelle Montgomery, Laura Parise, Randy Robbin, and John Savage, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Dr. Cannon: Consultant—Lilly, Sanofi; Employee—SelectHealth.

Dr. Gish: Consultant— Abbott, Abbvie, AccessBiologics, Alexion, Astra-Zeneca (Medimmune), Arbutus, Arrowhead, Bayer AG, Bristol-Myers Squibb Company, CoCrystal, Contravir, Eiger, Enyo, Genentech, Gilead Sciences, Hoffmann-LaRouche Ltd., HumAbs, Intercept, Intellia, Ionis, Janssen, Medimmune, Merck, Nanogen, Novira, Presido, Springbank, Theranos, VitalTherapies;

Consulting Confidentiality Agreements—AccessBiologics, Arbutus, Arrowhead, Contravir, Eiger, Genentech, HumAbs, Intellia, Intercept, Janssen, MedImmune, Novira, Presidio;

Grant/Research Support—AbbVie, Gilead, Merck;

Scientific Advisory Board— Abbvie, AccessBiologics, Astra-Zeneca (Medimmune), Arrowhead, Contravir, Eiger, Enyo, Genentach, Gilead, HumAbs, Intercept, Ionis, Intellia, Janssen, Merck,  Nongen, Quest;

Clinical Advisory Board – Arrowhead (Chair); Theranos

Promotional Speakers’ Bureau—AbbVie, Alexion, Bayer, BMS, Gilead Sciences Inc., Merck, Salix/Valeant;

Clinical Trials – Immuron, Intercept, Novo Nordisk, Oceta; Diagnostics – Theranos, Quest;

Drug Safety Monitoring Board – Ionis, Presidio, Novira;

Stock Shareholder – Alexion, Arrowhead, CoCrystal, Kinex, RiboSciences

Stock options: Arrowhead

Expert testimony: BMS, Janssen, USP Pharma

Dr. Manch: Consultant—Gilead; Speakers' Bureau—Abbvie.

Dr. Copeland and Dr. Dunn disclosed no relevant financial relationships with any commercial interest.

Ms. Brophy, Ms. Ciszeski, Ms. Johnson, Ms. Kuhn, Ms. Montgomery, Ms. Parise, Mr. Robbin, and Mr. Savage have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty have disclosed no off label/unapproved uses of drugs and/or devices will be discussed in the presentations.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity is supported by an educational grant from Gilead Sciences, Inc.